Boulder Care
Portland, Oregon, 97204, United States
Location status: Recruiting
Location contact
Andrea Baron, MPH
CONTACT
Laura Monico, PhD
CONTACT
Stephanie Papes
PRINCIPAL_INVESTIGATOR
NCT Number: NCT07169409
Our primary objective is to evaluate the ability of Boulder Care's telehealth-platform to create the necessary paradigmatic shift in Opioid Use Disorder (OUD) treatment to reach vulnerable populations, with targets that support both equitable and culturally-specific OUD treatment as well as business profitability.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Phase 1
Portland, Oregon, 97204, United States
Location status: Recruiting
Andrea Baron, MPH
CONTACT
Laura Monico, PhD
CONTACT
Stephanie Papes
PRINCIPAL_INVESTIGATOR
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
With this NIDA-funded grant, the study team will identify app-based treatment workflows that are demonstrably effective in low-resource settings: namely, telehealth services that are accessible without high-speed internet and deliberately helping patients transition into OUD care from relevant health and community system settings. An intentional focus on rural areas and Black and Hispanic demographics will help enhance health equity, and support solutions for payors.
Time frame: 48 weeks
To measure the participant intervention experience, the study team will utilize qualitative interview data with study participants. These data will be organized into the implementation science categories: Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM), and Feasibility of Intervention Measure (FIM).
The study team will determine whether each participant found the intervention to be feasible, acceptable, and/or appropriate. These findings will then be aggregated to better understand how participants experience the implementation of a telemedicine Opioid Use Disorder treatment organization, and will inform a future scaled-up implementation.
Time frame: 48 weeks
Items include: self-rated health, physically unhealthy days, mentally unhealthy days, and activity limitation days.
Values:
Self-rated health: 1 = Excellent, 2 = Very good, 3 = Good, 4 = Fair, 5 = Poor → Minimum = 1 (Excellent), Maximum = 5 (Poor)
Unhealthy days (physical/mental): Range 0-30 days in past 30 days
→ Minimum = 0, Maximum = 30
Direction: Higher scores = worse outcomes (more unhealthy days or poorer self-rated health).
Time frame: 48 weeks
Description: A 17-item multidimensional measure covering three domains:
Values:
Scoring and Direction:
Time frame: 48 weeks
Description: A single-item measure where participants rate their current intensity of craving for opioids by marking a point along a straight line (100 mm in length). The left anchor indicates "No craving at all" and the right anchor indicates "Most intense craving imaginable".
Values:
Minimum = 0 mm (no craving at all) Maximum = 100 mm (most intense craving imaginable)
Direction: Higher scores = worse outcome (greater opioid craving)
Contact information is provided by the study sponsor or research team.
Andrea Baron, MPH
CONTACT
Laura Monico, PhD
CONTACT
Boulder Care
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05589181
Chemically-Induced Disorders, Mental Disorders
Newark, New Jersey, United States
View Trial DetailsNCT07064564
Chemically-Induced Disorders, Mental Disorders
Millcreek, Utah, United States
View Trial DetailsNCT06969261
Chemically-Induced Disorders, Mental Disorders
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT05511909
Anxiety, Anxiety Disorders
Baltimore, Maryland, United States
View Trial Details